An RGD to LDV Motif Conversion within the Disintegrin Kistrin Generates an Integrin Antagonist That Retains Potency but Exhibits Altered Receptor Specificity
EVIDENCE FOR A FUNCTIONAL EQUIVALENCE OF ACIDIC INTEGRIN-BINDING MOTIFS*

(Received for publication, January 28, 1997, and in revised form, May 28, 1997)

Vicky H. Tselepis Dagger , Linda J. Green and Martin J. Humphries §

From the Wellcome Trust Centre for Cell-Matrix Research, School of Biological Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Integrin ligands almost invariably employ a variant of either the RGD or LDV motif as a key element of their receptor recognition site. These short acidic peptide sequences collaborate with specific nonhomologous flanking residues and spatially separate "synergy" sequences to determine receptor binding specificity. Although the consensus sequences for RGD and LDV motifs are quite different, their common use suggests that they might share a critical role in receptor-ligand engagement. To date, the effects of interconversion of the two motifs within a natural protein framework have not been tested; however, in this study, we have converted the natural RGD site found in the snake venom disintegrin kistrin into an LDV motif and examined the effects of the change on the specificity of integrin recognition and on disintegrin potency. While an assessment of receptor binding using cell adhesion and purified integrin solid-phase assays demonstrated recognition of recombinant RGD kistrin by alpha Vbeta 3 and alpha 5beta 1, a series of LDV kistrin chimeras did not bind to these integrins, but instead were recognized specifically by alpha 4beta 1. The minimal change to elicit this distinct switch in receptor specificity was found to involve alteration of only three residues within kistrin. Alanine scanning mutagenesis was used to provide further information on the functional contribution of the three residues. More important, the LDV kistrin chimeras also retained much of the characteristic potency of RGD kistrin, indicating that the kistrin scaffold is optimized for presentation of both RGD and LDV sequences. These findings provide evidence for similarities in motif pharmacophore and reinforce the hypothesis that RGD and LDV sites have an equivalent functional role in receptor binding. They also demonstrate the potential for other disintegrin-containing proteins, perhaps from the ADAM family, to employ LDV sequences for integrin binding.


INTRODUCTION

Cell-surface adhesion receptors mediate the cell-cell and cell-matrix interactions that are fundamental to normal cell behavior and tissue organization. The integrins, a superfamily of structurally related alpha beta heterodimers, represent a major class of adhesion receptors (for reviews, see Refs. 1-4).

Many studies of the molecular basis of integrin-ligand binding have now been performed, and frequently, integrins have been found to recognize short peptide motifs within their ligands. The RGD motif, which contains a critical aspartate residue, was first identified in the central cell-binding domain of fibronectin (5-7), but has subsequently been shown to be functional in other molecules, including vitronectin and von Willebrand factor. The molecular mechanisms involved in the recognition of the RGD sequence are complex since it binds to a number of different integrins, and receptor specificity varies between different matrix molecules. A second peptide motif, LDV, present within the alternatively spliced CS1 sequence of the IIICS region of fibronectin, also contains a crucial aspartate and is primarily recognized by integrin alpha 4beta 1 (8-10). The integrin-binding members of the immunoglobulin superfamily possess motifs that are homologous to LDV, including the tetrapeptide sequence IDSP in domains 1 and 4 of VCAM-1 (11-14) and glutamate-containing sequences in the membrane-distal domains of intercellular adhesion molecules (15-17). A third aspartate-dependent motif, which contains QAGDV as the minimal active sequence, is found near the C terminus of the gamma  chain of human fibrinogen and is recognized by platelet integrin alpha IIbbeta 3 (18).

The active-site motifs of integrin ligands can be reproduced synthetically in the form of peptides, and these reagents have been instrumental in providing information on the specificities of receptor-ligand binding and for the development of therapeutic agents for diseases involving aberrant adhesion (19). In addition, the insertion of peptide motifs into nonadhesive protein scaffolds has previously been reported to generate adhesive activity. The RGD sequence has been incorporated into a long exposed loop within human lysozyme by site-directed mutagenesis, and the resultant mutant protein was able to promote cell adhesion (20). Insertion of RGD into the finger-like structure of hirudin produced a molecule capable of inhibiting platelet aggregation (21). Both the RGD- and LDV-containing CS1 sequences have been successfully grafted into staphylococcal protein A, with the creation of the cell adhesive activities of both motifs (22, 23).

Although short sequence motifs such as RGD and LDV are critical for integrin recognition, they do not account for the entire binding event, as synergistic sequences have been identified that collaborate with them (24, 25), and nonfunctional RGD and LDV sequences are also present in many molecules. The affinity and selectivity of linear peptides can be improved by the introduction of a conformational constraint, for example, by cyclization (7, 26). Thus, differences in conformation, flanking residues, and the use of synergy sequences may all contribute to the binding specificities of different integrin-ligand combinations.

A conformationally constrained, functional RGD motif is also found within many disintegrins, a family of naturally occurring polypeptide integrin antagonists present in snake venoms (for reviews, see Refs. 27-29). Disintegrins inhibit platelet aggregation by blocking the adhesive function of integrin alpha IIbbeta 3 (30), but are also able to disrupt the adhesive functions of other RGD-dependent integrins and are therefore relatively nonspecific (31-33). It is notable that disintegrins are up to 1000-fold more potent than linear RGD-containing peptides (34), probably because the RGD sequence exists in a favorable conformation at the apex of a long loop across the surface of the molecule (35).

The disintegrin molecule may be considered as a model scaffold for the presentation of an integrin recognition motif, and in this study, we have examined the effects of engineering the replacement of the RGD sequence in the disintegrin kistrin with LDV to assess whether it is possible to retain potency in an integrin antagonist while altering specificity. We have reported in preliminary form the design of synthetic kistrin cDNA and the expression of the molecule as a recombinant protein in which specific residues or segments can be mutated to create chimeric kistrins (36).


EXPERIMENTAL PROCEDURES

Materials

Rat mAb1 13 (IgG), recognizing the human integrin beta 1 subunit, and rat mAb 16 and mAb 11 (IgG), recognizing the human integrin alpha 5 subunit, were gifts from S. K. Akiyama (NIDR, National Institutes of Health, Bethesda, MD) (37). Mouse mAb HP2/1 (IgG), recognizing the human integrin alpha 4 subunit, was purchased from Serotec Ltd. (Oxford, United Kingdom). LM609 mAb (ascites), recognizing human integrin alpha Vbeta 3, was a gift from D. A. Cheresh (Scripps Research Institute, La Jolla, CA), and mAb 17E6 (IgG), recognizing the human integrin alpha V subunit, was from S. Goodman (E. Merck, Darmstadt, Germany). Mouse anti-human mAb P1E6 (ascites), recognizing the integrin alpha 2 subunit, was obtained from GIBCO (Paisley, Scotland). All anti-integrin antibodies used were function-blocking, with the exception of mAb 11. An 80-kDa fragment of plasma fibronectin containing the central cell-binding domain was generated as described (38). H/120, a recombinant fragment of fibronectin containing the HepII/IIICS region, was produced as described (39). Integrin alpha 4beta 1 was isolated from the MOLT-4 human T lymphoblastic cell line as described (39). Integrin alpha 5beta 1 was purified from human placenta as described (40).

Cloning and Expression of Recombinant Kistrin

Kistrin cDNA was generated from complementary oligonucleotides designed from the protein sequence using Escherichia coli codon usage data. BamHI and EcoRI restriction enzyme sites were incorporated at the ends of the cDNA sequence to allow cloning into the phagemid vector pUC118. Internal BspMII, NarI, BglII, and KspI restriction sites were also incorporated to allow exchange of different segments of the molecule (Fig. 1). The complementary phosphorylated oligonucleotides were annealed and ligated into the dephosphorylated vector pUC118. Competent E. coli DH5alpha F' cells were transformed with the ligation product, and the kistrin cDNA sequence was verified before subcloning into the pGEX2T expression vector (Pharmacia Biotech, Milton Keynes, UK) using the same restriction sites. DH5alpha F' cells were transformed, and glutathione S-transferase-kistrin fusion proteins were induced and isolated as described (41). Briefly, a 40-ml overnight culture of transformed DH5alpha F' cells was diluted 1:10 with fresh LB medium containing 50 µg/ml ampicillin and cultured for 1 h at 37 °C. Isopropyl-beta -D-thiogalactopyranoside was added to 0.1 M and cultured for a further 4 h. Cells were then centrifuged, resuspended in divalent cation-free Dulbecco's phosphate-buffered saline, and lysed by sonication. The extract was cleared by centrifugation and applied to a glutathione-agarose affinity column (Sigma, Poole, UK) pre-equilibrated with 150 mM NaCl and 10 mM Tris-HCl, pH 7.5. The column was washed with 150 mM NaCl and 10 mM Tris-HCl, pH 7.5, and the fusion protein was eluted with 5 mM reduced glutathione and 50 mM Tris-HCl, pH 7.5. The glutathione S-transferase carrier was removed by cleavage with human thrombin (Sigma) for 3 h at room temperature using an enzyme/substrate ratio of 1:500 (w/w). A second glutathione-agarose column was used to separate kistrin from GST, with the kistrin appearing in the column flow-through fraction. Protein concentrations were measured using the BCA assay (Pierce, Chester, UK), and peak fractions were stored at -70 °C.


Fig. 1. A, amino acid and nucleotide sequences of recombinant kistrin with codons selected using E. coli codon usage data. The sequence of the RGD loop is shown in boldface. B, the complementary oligonucleotides used to generate kistrin cDNA, showing restriction enzyme sites in boldface. The nucleotide sequence encoding the RGD loop is underlined.
[View Larger Version of this Image (33K GIF file)]

Production of Mutant Kistrins

The segment of cDNA encoding the kistrin RGD loop was removed by digestion with BglII and KspI restriction endonucleases and replaced with a double-stranded insert encoding a mutant sequence. The insert was generated from two complementary oligonucleotides that were annealed, phosphorylated, and ligated into the dephosphorylated vector. Competent DH5alpha F' cells were transformed with the ligation product, and the correct sequence was verified before expression of the mutant kistrins as described above.

Characterization of Recombinant Kistrins

The purity of the recombinant kistrins was assessed by discontinuous SDS-polyacrylamide gel electrophoresis using a Tris/Tricine buffer system (42). The fidelity of bacterial translation and thrombin cleavage were validated by N-terminal sequencing and mass spectroscopy.

N-terminal Sequencing

Prior to analysis, recombinant kistrin was dialyzed extensively at 4 °C against 0.1% (v/v) trifluoroacetic acid. Approximately 1-nmol samples were sequenced by automated Edman degradation and high pressure liquid chromatography using a Model 476A Protein Sequencer (Applied Biosystems, Warrington, Cheshire, UK). The sequence obtained for recombinant kistrin was GSGKEXDXS(G/S)PENPXXD, which is identical to that of authentic kistrin with the exception of the ambiguous position, which is actually Ser, and the initial Gly and Ser, which are derived from the GST fusion partner following thrombin cleavage. The four unidentified residues (X) are cysteines that are destroyed during sequencing.

Mass Spectrometry

Recombinant kistrins were analyzed by matrix-assisted laser desorption time-of-flight mass spectrometry using a VG-TofSpec E spectrometer (Fisons Instruments, Manchester, UK). A mass of 7469 obtained for recombinant RGD kistrin was within 0.1% of the calculated mass of 7474.5 based on the amino acid sequence. For ILDV kistrin, the value of 7451 obtained was also within 0.1% of the calculated mass of 7474.5.

Solid-phase Receptor-Ligand Binding Assay

Assays were performed using a method based on that of Charo et al. (43). The 80-kDa fragment of fibronectin (500 µg/ml in PBS) or the H/120 recombinant fragment of fibronectin (450 µg/ml) was biotinylated by mixing with an equal mass of sulfo-N-hydroxysuccinimidobiotin (Pierce). After rotary mixing for 40 min at room temperature, excess biotin was removed from the mixture by dialyzing against several changes of 150 mM NaCl and 25 mM Tris-HCl, pH 7.4. A 96-well enzyme-linked immunosorbent assay plate (Immulon-3, Dynatech, Billingshurst, UK) was incubated overnight at room temperature with 100-µl aliquots of purified integrins diluted with PBS to a concentration of ~5 µg/ml. The wells were then blocked with 200 µl of 5% (w/v) BSA, 150 mM NaCl, 0.05% (w/v) NaN3, and 25 mM Tris-HCl, pH 7.4, for 2 h at room temperature and washed three times with 200 µl of 150 mM NaCl, 5 mM MnCl2, and 25 mM Tris-HCl, pH 7.4, containing 1 mg/ml BSA (buffer A). 100-µl aliquots of biotinylated H/120 (~0.2 µg/ml), diluted with buffer A, with or without recombinant kistrins, were then added to the wells and incubated at 30 °C for 3 h. Unbound biotinylated ligand was removed, and the wells were washed three times with buffer A. Bound ligand was quantitated by addition of 100 µl of ExtrAvidin-peroxidase conjugate (Sigma) diluted 1:200 in buffer A for 10 min at room temperature, following which the wells were washed four times with buffer A. The color was developed by addition of 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma), and the absorbance was measured at 405 nm. Nonspecific binding was determined from the level of ligand binding to BSA alone, and these values were subtracted from those obtained with integrin-coated wells. Each point represented the mean ± S.D. of four replicate wells.

Cell Spreading Assay

The A375-SM human melanoma cell line (provided by I. J. Fidler, M. D. Anderson Hospital and University of Texas, Houston, TX) was maintained as described (44) in Eagle's minimal essential medium supplemented with 10% (v/v) fetal bovine serum, minimal essential medium vitamins, nonessential amino acids, 2 mM L-glutamine, and 1 mM sodium pyruvate. HT-1080 human fibrosarcoma cells were obtained from the European Collection of Animal Cell Cultures (Porton Down, UK) and cultured in Dulbecco's modified Eagle's medium containing 0.11 g/liter sodium pyruvate, 10% (v/v) fetal bovine serum, and 2 mM L-glutamine. Assays were performed as described by Humphries et al. (45) using 96-well tissue culture plates (Costar, High Wycombe, Bucks, UK). Ligands were diluted in Dulbecco's phosphate-buffered saline (PBS), and 100-µl aliquots were used to coat the wells for 1 h at room temperature. The ligand solution was then removed, and sites that could support nonspecific cell adhesion were blocked with 100 µl of 10 mg/ml heat-denatured BSA (45). After incubation for 30 min at room temperature, the BSA was removed, and 50-µl aliquots of inhibitors in PBS were added. Cells were detached using 0.05% (w/v) trypsin and 0.02% (w/v) EDTA and then washed and resuspended to 2 × 105 cells/ml in Dulbecco's minimal essential medium. Cell suspensions were allowed to recover at 37 °C for 10 min before addition of 50-µl aliquots to the wells. Following incubation at 37 °C for 90 min in a humidified atmosphere of 6% CO2, cells were fixed with 5% (w/v) glutaraldehyde in PBS. Using phase-contrast microscopy, the percentage of cells with a flattened, phase-dark morphology was estimated. Each point was obtained by counting 3 × 100 cells in random fields. No cell spreading was observed on wells coated only with heat-denatured BSA.


RESULTS

The disintegrin kistrin was selected for use as a scaffold for the insertion of the LDV motif because the sequence of the RGD loop shows some homology to the LDV-containing CS1 sequence in fibronectin. In both sequences, the critical aspartate is immediately followed by a residue with a hydrophobic side chain, and a proline residue is present on either side of the motif: kistrin RGD loop sequence, RIPRGDMPDDR; and CS1 sequence, PEILDVPSTV. Synthetic kistrin cDNA was generated from overlapping oligonucleotides and expressed as a recombinant protein in E. coli. Samples of recombinant kistrin (r-kistrin) from different stages of purification were analyzed by SDS-polyacrylamide gel electrophoresis (Fig. 2). The r-kistrin was resolved as a slightly diffuse band of ~7.5 kDa under both reducing and nonreducing conditions, which corresponds with its expected molecular mass. The band at 26 kDa was the major contaminant, but was removed by repeating the glutathione-agarose affinity chromatography and therefore appeared to be GST (data not shown).


Fig. 2. Purification of ILDV kistrin. Samples were resolved under reducing conditions on a 15% SDS-polyacrylamide gel, and bands were visualized by staining with Coomassie Blue. Equivalent amounts were loaded in lanes 2-4 only. The molecular masses of standards (in kilodaltons) are indicated on the left. Lane 1, molecular mass standards; lane 2, cell pellet; lane 3, sonicated extract; lane 4, flow-through fraction from the first column; lane 5, first column eluate; lane 6, thrombin-cleaved eluate; lane 7, flow-through fraction from the second column.
[View Larger Version of this Image (49K GIF file)]

Following the expression of kistrin as a recombinant protein, the activity of r-kistrin was compared with that of native kistrin isolated from venom. The ability of both molecules to inhibit the spreading of A375-SM cells on the RGD-containing 80-kDa fragment of fibronectin, which is recognized by integrins alpha 5beta 1 and alpha Vbeta 3, was examined (Fig. 3). Half-maximal inhibition of cell spreading was obtained at 2 µM for native kistrin and at 7 µM for the recombinant molecule. When compared with the published value of 100 µM for the linear peptide GRGDS (34), these data demonstrate that both native and recombinant kistrins are potent integrin antagonists; they also suggest that the recombinant molecules are largely correctly folded. The biological activity of disintegrins appears to be dependent on correct disulfide bond-mediated folding, as suggested by the dramatic loss of activity following reduction and alkylation of the disulfide bonds, but nevertheless, E. coli appears to be a suitable host for their recombinant expression (31, 46).


Fig. 3. Comparison of the effect of recombinant (open circles) and native (closed circles) kistrins on A375-SM cell spreading on the 80-kDa fragment of fibronectin coated at 10 µg/ml. Error bars indicate S.D.
[View Larger Version of this Image (16K GIF file)]

Having established the anti-adhesive activity of recombinant kistrin, the synthetic cDNA was used as a template for the creation of chimeras with different integrin recognition motifs. In the initial chimera targeting the RGD loop, the entire 11-residue loop sequence was removed by excision of the segment of cDNA encoding this region and replaced with a segment encoding an 11-amino acid sequence from the C-terminal end of the CS1 peptide of fibronectin. A second chimera in which the RGDM tetrapeptide sequence from the loop was replaced by ILDV was also generated, the minimal change needed to convert RGD to LDV. In further mutagenesis, the contribution of individual residues to the activity of the molecule was investigated by replacement with alanine. The active-site aspartate was retained in the same position as in the native kistrin sequence in all mutants. The amino acid sequences of the RGD loop were as follows: r-kistrin, CRIPRGDMPDDRC; CS1 kistrin, CGPEILDVPSTVC; ILDV kistrin, CRIPILDVPDDRC; ALDV kistrin, CRIPALDVPDDRC; IADV kistrin, CRIPIADVPDDRC; ILAV kistrin, CRIPILAVPDDRC; and AAAV kistrin, CRIPAAAVPDDRC.

Promotion of Cell Spreading by Recombinant Kistrin Fusion Proteins

To compare the abilities of mutant kistrins to promote cell spreading, they were purified as fusion proteins retaining the GST carrier and immobilized on the surface of 96-well plates. A high maximal level (>95%) of HT-1080 cell spreading was observed on GST-r-kistrin containing the native sequence, with half-maximal spreading at a coating concentration of 1.1 µg/ml. HT-1080 cell spreading was not supported by any of the mutants (Fig. 4 and data not shown).


Fig. 4. Spreading of HT-1080 cells on GST-kistrin fusion proteins. Closed circles, GST-kistrin; open square, GST-ILDV kistrin. Error bars indicate S.D.
[View Larger Version of this Image (13K GIF file)]

Since A375-SM cells express integrin alpha 4beta 1 and recognize the ILDV motif within the CS1 sequence of fibronectin, spreading assays were performed to determine whether these cells were able to recognize the ILDV motif in kistrin chimeras (Fig. 5). Dose-dependent promotion of spreading was observed, but activity varied between the different mutant kistrins. GST-r-kistrin supported up to 98% spreading, with half-maximal spreading observed at a coating concentration of 0.7 µg/ml. Half-maximal spreading was supported at 7.4 µg/ml by the ILDV kistrin chimera and at 19 µg/ml by the ALDV kistrin mutant. Cell spreading on either the IADV kistrin or CS1 kistrin fusion proteins reached a maximum of 20% at ~200 µg/ml (data not shown). No cell spreading was observed on GST alone or on the two mutants AAAV kistrin and ILAV kistrin. The results of the cell spreading assay were mirrored by A375-SM cell attachment assays (data not shown).


Fig. 5. Spreading of A375-SM cells on GST-kistrin fusion proteins. Closed circles, GST-kistrin; open squares, GST-ILDV kistrin; closed triangles, GST-CS1 kistrin; open inverted triangles, GST-ALDV kistrin; closed diamonds, GST-IADV kistrin; open hexagons, GST-ILAV kistrin. Error bars indicate S.D.
[View Larger Version of this Image (21K GIF file)]

Effect of Anti-integrin Antibodies on Cell Spreading on Fusion Proteins

To investigate which receptors were used by the HT-1080 and A375-SM cells to spread on the kistrin chimeras, the effects of function-blocking anti-integrin antibodies were tested. The effects of anti-integrin antibodies on the spreading of HT-1080 cells on RGD kistrin are shown in Fig. 6. Spreading was partially inhibited by function-blocking anti-alpha 5 (33%), anti-alpha V (43%), anti-beta 1 (46%), and anti-alpha Vbeta 3 (40%) antibodies, but not by anti-alpha 4 or anti-alpha 2 antibodies. Substantial inhibition was observed when anti-beta 1 and anti-alpha Vbeta 3 (97%) antibodies or when anti-alpha 5 and anti-alpha V (95%) antibodies were used together. A combination of anti-alpha 5 and anti-alpha Vbeta 3 antibodies gave ~77% inhibition of spreading. These data suggest that the receptors used by HT-1080 cells to recognize r-kistrin are integrins alpha Vbeta 3, alpha 5beta 1, and possibly alpha Vbeta 1.


Fig. 6. Effects of anti-integrin antibodies on HT-1080 cell spreading on GST-kistrin fusion protein. The coating concentration of GST-kistrin was 10 µg/ml. C represents spreading in the absence of antibody. Antibodies were used at 10 µg/ml, with the exception of HP2/1, which was used at 20 µg/ml, and 17E6, which was used at 5 µg/ml. Error bars indicate S.D.
[View Larger Version of this Image (61K GIF file)]

Spreading of A375-SM cells on RGD kistrin (Fig. 7A) was substantially inhibited by anti-alpha V (85%) and anti-alpha Vbeta 3 (73%) antibodies and was slightly reduced by anti-alpha 5 (14%) and anti-beta 1 (14%) antibodies. These data suggest that A375-SM cells employ alpha Vbeta 3 as the primary receptor for r-kistrin, but that alpha 5beta 1 may also have a minor contribution. A375-SM cell spreading on ILDV kistrin (Fig. 7B), CS1 kistrin (Fig. 7C), ALDV kistrin (Fig. 7D), and IADV kistrin (Fig. 7E) was almost completely blocked by anti-beta 1 and anti-alpha 4 antibodies, suggesting that the melanoma cells were using integrin alpha 4beta 1 only for spreading on these chimeras.


Fig. 7. Effects of anti-integrin antibodies on A375-SM cell spreading on 1 µg/ml GST-kistrin (A), 25 µg/ml GST-ILDV kistrin (B), 50 µg/ml GST-CS1 kistrin (C), 25 µg/ml GST-ALDV kistrin (D), and 25 µg/ml GST-IADV kistrin (E). C represents spreading in the absence of antibody. Antibodies were used at the concentrations described in the legend to Fig. 6. Error bars indicate S.D.
[View Larger Version of this Image (42K GIF file)]

Inhibition of Integrin-Ligand Binding by Recombinant Kistrins in Solid-phase Assay

To measure the potency of recombinant kistrins and to exclude the possibility that the mutant kistrins were exerting their effects indirectly, for example, via another cell-surface receptor, the interactions of the mutant kistrins with purified integrins in solid-phase assays were examined. RGD kistrin was found to be a potent inhibitor of the binding of the RGD-containing 80-kDa fibronectin fragment to immobilized alpha 5beta 1 (Fig. 8), with half-maximal inhibition being observed at 0.01 µM. None of the mutant chimeras showed any inhibitory activity when tested at concentrations of up to 1.2 µM (Fig. 8 and data not shown).


Fig. 8. Inhibition of the binding of 80-kDa fibronectin to alpha 5beta 1 in solid-phase assays by recombinant kistrins. Biotinylated 80-kDa fibronectin was allowed to bind to alpha 5beta 1 in the presence of various concentrations of r-kistrins. Closed circles, r-kistrin; open squares, ILDV kistrin; closed triangles, CS1 kistrin. Data are expressed as the mean of four replicate wells. Error bars indicate S.D.
[View Larger Version of this Image (15K GIF file)]

ILDV kistrin was the most potent inhibitor of the binding of the LDV-containing H/120 fibronectin fragment to immobilized alpha 4beta 1 (with half-maximal inhibition at ~0.1 µM). The relative activities of the alanine replacement mutants followed the same pattern as for the promotion of melanoma cell spreading and attachment, with half-maximal inhibition observed at ~0.12 µM for ALDV kistrin and at 0.79 µM for IADV kistrin (Fig. 9A). Half-maximal inhibition was not achieved with either AAAV kistrin or ILAV kistrin at concentrations up to 3.6 µM. The ability of the chimeras to block the function of purified alpha 4beta 1 therefore correlated with the ability to promote alpha 4beta 1-dependent cell spreading.


Fig. 9. Inhibition of the binding of H/120 to alpha 4beta 1 in solid-phase assays by recombinant kistrins. Biotinylated H/120 was allowed to bind to alpha 4beta 1 in the presence of various concentrations of r-kistrin. Data are expressed as the mean of four separate wells. Error bars indicate S.D. A: closed circles, ILDV kistrin; open squares, ILAV kistrin; open inverted triangles, ALDV kistrin; closed diamonds, AAAV kistrin; closed triangles, IADV kistrin. B: closed circles, CS1 kistrin; open squares, r-kistrin; closed triangles, ILDV kistrin.
[View Larger Version of this Image (12K GIF file)]

RGD kistrin and CS1 kistrin were less potent antagonists of alpha 4beta 1 than ILDV kistrin (Fig. 9B). Half-maximal inhibition was not achieved at concentrations up to 3.5 µM for CS1 kistrin, but was observed at 2.7 µM for RGD kistrin. The different potencies of the recombinant kistrins in Fig. 9 are likely to be a reflection of their relative affinities for the integrin receptors, but it is also conceivable that this might be attributed to selective inhibition of different integrin activation states. Although Mn2+ was included in all of the solid-phase assays to maximize integrin activation, a proportion of the integrin population may nevertheless have remained in an inactive conformation.


DISCUSSION

The aims of this study were to express kistrin (and kistrin chimeras) in recombinant form and to examine for the first time the effects of interconverting integrin recognition motifs within a natural framework on receptor binding potency and specificity. Our major findings are as follows. (i) Recombinant and native kistrins exhibit similar potency and specificity, confirming previous studies that have reported successful bacterial expression of disintegrins. (ii) A chimeric kistrin containing a minimal RGD to LDV motif change exhibits a distinct switch in receptor specificity: RGD kistrin recognizes alpha 5beta 1 and alpha Vbeta 3, whereas ILDV kistrin binds specifically to alpha 4beta 1. (iii) The ILDV kistrin chimera retains much of the potency of the parent RGD kistrin, suggesting that the structural features required for a potent RGD activity also apply to the LDV motif. This provides further evidence that the RGD and LDV motifs may be functionally equivalent. (iv) Alanine replacement mutants within the LDV motif have provided information on the relative contributions of individual flanking residues to integrin binding activity.

The receptor binding specificity of recombinant kistrins was assessed both by solid-phase assays and by inhibition of cell spreading by anti-integrin antibodies. Spreading of both HT-1080 and A375-SM cells on r-kistrin was inhibited by anti-alpha Vbeta 3, anti-alpha V, anti-beta 1, and anti-alpha 5 antibodies, and r-kistrin was able to bind to purified alpha 5beta 1 in solid-phase assays. These data suggest that r-kistrin is recognized by integrin alpha Vbeta 3 and with a lower affinity by alpha 5beta 1 and also possibly by alpha Vbeta 1. Previous studies have suggested that the hydrophobic methionine residue immediately C-terminal to RGD in kistrin is responsible for a reduced affinity for alpha 5beta 1 and alpha Vbeta 3 compared with alpha IIbbeta 3 (47, 48); however, alpha Vbeta 3 seems to be tolerant of a more diverse flanking region than alpha 5beta 1 (49), which may explain the significant contribution of alpha Vbeta 3 to the adhesion of both A375-SM and HT-1080 cells to r-kistrin.

The ILDV kistrin chimera was unable to bind to purified alpha 5beta 1, but bound to alpha 4beta 1, and cell spreading on ILDV kistrin was inhibited only by anti-alpha 4 and anti-beta 1 antibodies. These results suggest that ILDV kistrin is recognized by alpha 4beta 1, but not by alpha Vbeta 3 or alpha 5beta 1, indicating that alteration of only three residues is sufficient to achieve a major change in specificity. The results of the alanine replacement mutagenesis reflect the dependence on the aspartate residue for the activity of ILDV kistrin and the relative importance of the isoleucine and leucine residues, the requirement for the leucine being greater than for isoleucine.

Although the ILDV kistrin chimera is potent, the CS1 kistrin chimera is considerably less active, although both share the ILDVP pentapeptide sequence at the same position in the loop. The differences in sequence between the two lie in the flanking sequences RIP, immediately N-terminal, and DDR, immediately C-terminal to ILDVP, and it is likely that they determine the potency of the kistrin molecule. Further mutagenesis will reveal the contribution of these sequences to the activity of ILDV kistrin. It has been suggested that the RGD tripeptide is chiefly responsible for the activity of kistrin (50), but there is also evidence that the surrounding amino acids contribute to the affinity and selectivity of disintegrins (51-53). It may also be possible that the residues in the loop contribute differently to the binding of alpha 4beta 1 to ILDV kistrin than to the binding interactions between alpha Vbeta 3 and r-kistrin. For example, the proline residues lying N- and C-terminal to the RGD motif in kistrin are not present in the known RGD loop sequences of most other disintegrins, and alanine replacement mutagenesis suggests that they are not critical to the potency of kistrin (50), but may contribute to the activity of ILDV kistrin.

The kistrin RGD loop is conformationally flexible but more constrained than a linear peptide, possibly contributing to the potency of the molecule. The concentration of the linear CS1 peptide required to give half-maximal inhibition of H/120 binding to alpha 4beta 1 in a solid-phase assay has been quoted as 4 µg/ml (1.5 µM) (39) and is therefore significantly more active than the CS1 kistrin chimera. The 11-residue sequence inserted into the kistrin RGD loop may be unfavorably constrained, resulting in low affinity interactions with alpha 4beta 1. Clearly, specific residues or sequences must be present within the loop to produce a potent integrin inhibitor.

Our finding that it is possible to exchange RGD and LDV motifs (by exchanging only three residues) in an integrin ligand and alter specificity but retain activity suggests a functional equivalence between the two motifs. Earlier evidence for this was obtained from cross-inhibition studies in which short linear RGD peptides were shown to inhibit alpha 4beta 1-LDV interactions competitively (34), and certain cyclic RGD peptides have been produced that were also able to block alpha 4beta 1 (54, 55). This may explain our finding that r-kistrin was able to inhibit the adhesive activity of purified alpha 4beta 1 in the solid-phase assay. The QAGDV motif is also thought to be functionally equivalent to RGD since QAGDV- and RGD-containing peptides share common or mutually exclusive binding sites on alpha IIbbeta 3 (56).

The aspartate residue critical to the activity of all three motifs may be central to a common integrin-binding mechanism used by these sequences. Integrin-ligand binding and receptor activation are dependent on divalent cations, and ligand-binding sites within integrins coincide with putative cation-binding sites (57, 58). It has been proposed that a divalent cation could be coordinated simultaneously by the ligand motif and the active site within the integrin, with the acidic aspartate side chain providing a cation-coordinating group (59, 60). Subtle differences in motif conformation between ligands and the use of synergy sequences may provide the basis for receptor specificity. In the future, it may be possible to exploit kistrin (or other disintegrin) scaffolds to display different integrin recognition sequences and to generate potent inhibitors that can be used in vivo as probes of adhesive function or for structural analysis.

Finally, it is conceivable that other disintegrins might naturally express an LDV motif. A gene family known as ADAM (for proteins containing a disintegrin and metalloproteinase domain) encodes a family of membrane-anchored proteins in mammals that may play roles in cell-cell interactions (61, 62). Whereas almost all snake venom disintegrins contain an RGD active site, the only ADAM protein that contains RGD in its disintegrin domain that has been identified to date is the molecule metargidin (63). Other ADAM proteins lack this sequence and instead have a motif that includes highly conserved cysteine and aspartate residues and that bears some homology to an LDV motif. As yet, the integrin binding specificity of ADAM proteins and the role of this active site sequence are poorly understood, but it is conceivable that they may be natural LDV forms of disintegrins.


FOOTNOTES

*   This work was supported in part by grants from the Wellcome Trust (to M. J. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Postgraduate student supported by Glaxo Wellcome.
§   To whom correspondence should be addressed: Wellcome Trust Centre for Cell-Matrix Research, School of Biological Sciences, University of Manchester, 2.205 Stopford Bldg., Oxford Rd., Manchester M13 9PT, UK. Tel./Fax: 44-161-275-5071; E-mail: martin.humphries{at}man.ac.uk.
1   The abbreviations used are: mAb, monoclonal antibody; GST, glutathione S-transferase; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; PBS, phosphate-buffered saline; BSA, bovine serum albumin; r-kistrin, recombinant kistrin.

ACKNOWLEDGEMENTS

We are grateful to Paul Mould for providing the 80-kDa fragment of fibronectin and integrin alpha 5beta 1, to Kath Clark for integrin alpha 4beta 1, to Cath Fernandez for the N-terminal sequencing, and to Janet Askari and Sue Craig for H/120.


REFERENCES

  1. Hynes, R. (1992) Cell 69, 11-25 [Medline] [Order article via Infotrieve]
  2. Schwarz, M. A., Schaller, M. D., and Ginsberg, M. H. (1995) Annu. Rev. Cell Dev. Biol. 11, 549-599 [CrossRef][Medline] [Order article via Infotrieve]
  3. Yamada, K. M., and Miyamoto, S. (1995) Curr. Opin. Cell Biol. 7, 681-689 [CrossRef][Medline] [Order article via Infotrieve]
  4. Humphries, M. J. (1996) Curr. Opin. Cell Biol. 8, 632-640 [CrossRef][Medline] [Order article via Infotrieve]
  5. Pierschbacher, M. D., and Ruoslahti, E. (1984) Nature 309, 30-33 [Medline] [Order article via Infotrieve]
  6. Yamada, K. M., and Kennedy, D. W. (1984) J. Cell Biol. 99, 29-36 [Abstract/Free Full Text]
  7. Pierschbacher, M. D., and Ruoslahti, E. (1987) J. Biol. Chem. 262, 17294-17298 [Abstract/Free Full Text]
  8. Wayner, E. A., Garcia-Pardo, A., Humphries, M. J., McDonald, J. A., and Carter, W. G. (1989) J. Cell Biol. 109, 1321-1330 [Abstract]
  9. Mould, A. P., Wheldon, L. A., Komoriya, A., Wayner, E. A., Yamada, K. M., and Humphries, M. J. (1990) J. Biol. Chem. 265, 4020-4024 [Abstract/Free Full Text]
  10. Komoriya, A., Green, L. J., Mervic, M., Yamada, S. S., Yamada, K. M., and Humphries, M. J. (1991) J. Biol. Chem. 266, 15075-15079 [Abstract/Free Full Text]
  11. Clements, J. M., Newham, P., Shepherd, M., Gilbert, R., Dudgeon, T. J., Needham, L. A., Edwards, R. M., Berry, L., Brass, A., and Humphries, M. J. (1994) J. Cell Sci. 107, 2127-2135 [Abstract/Free Full Text]
  12. Osborn, L., Vassallo, C., Browning, B. G., Tizard, R., Haskard, D. O., Benjamin, C. D., Dougas, I., and Kirchhausen, T. (1994) J. Cell Biol. 124, 601-608 [Abstract]
  13. Renz, M. E., Chiu, H. H., Jones, S., Fox, J., Kim, K. J., Presta, L. G., and Fong, S. (1994) J. Cell Biol. 125, 1395-1406 [Abstract]
  14. Vonderheide, R. H., Tedder, T., Springer, T. A., and Staunton, D. A. (1994) J. Cell Biol. 125, 215-222 [Abstract]
  15. Staunton, D. E., Dustin, M. L., Erickson, H. P., and Springer, T. A. (1990) Cell 61, 243-254 [Medline] [Order article via Infotrieve]
  16. Li, R., Nortamo, P., Valmu, L., Tolvanen, M., Huuskonen, J., Kantor, C., and Gahmberg, C. G. (1993) J. Biol. Chem. 268, 17513-17518 [Abstract/Free Full Text]
  17. Holness, C. L., Bates, P. A., Littler, A. J., Buckley, C. D., McDowall, A., Bossy, D., Hogg, N., and Simmons, D. L. (1995) J. Biol. Chem. 270, 877-884 [Abstract/Free Full Text]
  18. Kloczewiak, M., Timmons, S., Lukas, T. J., and Hawiger, J. (1984) Biochemistry 23, 1767-1774 [Medline] [Order article via Infotrieve]
  19. Humphries, M. J., Doyle, P. M., and Harris, C. J. (1994) Exp. Opin. Ther. Patents 4, 227-235
  20. Yamada, T., Matshushima, M., Inaka, K., Ohkubu, T., Uyeda, A., Maeda, T., Titani, K., Sekiguchi, K., and Kikuchi, M. (1993) J. Biol. Chem. 268, 10588-10592 [Abstract/Free Full Text]
  21. Knapp, A., Degenhardt, T., and Dodt, J. (1992) J. Biol. Chem. 267, 24230-24234 [Abstract/Free Full Text]
  22. Maeda, T., Oyama, R., Ichihara-Tanaka, K., Kimizuka, F., Kato, I., Titani, K., and Sekiguchi, K. (1989) J. Biol. Chem. 264, 15165-15168 [Abstract/Free Full Text]
  23. Maeda, T., Oyama, R., Titani, K., and Sekiguchi, K. (1993) J. Biochem. (Tokyo) 113, 29-35 [Abstract]
  24. Aota, S., Nomizu, M., and Yamada, K. M. (1994) J. Biol. Chem. 269, 24756-24761 [Abstract/Free Full Text]
  25. Bowditch, R. D., Hariharan, M., Tominna, E. F., Smith, J. W., Yamada, K. M., Getzoff, E. D., and Ginsberg, M. H. (1994) J. Biol. Chem. 269, 10856-10863 [Abstract/Free Full Text]
  26. O'Neil, K. T., Hoess, R. H., Jackson, S. A., Ramachandran, N. S., Mousa, S. A., and DeGrado, W. F. (1992) Proteins Struct. Funct. Genet. 14, 509-515 [Medline] [Order article via Infotrieve]
  27. Blobel, C. P., and White, J. M. (1992) Curr. Opin. Cell Biol. 4, 760-765 [Medline] [Order article via Infotrieve]
  28. Lazarus, R. A., and McDowell, R. S. (1993) Curr. Opin. Cell Biol. 4, 438-445
  29. Niewiarowski, S., McLane, M. A., Kloczewiak, M., and Stewart, G. J. (1994) Semin. Hematol. 31, 289-300 [Medline] [Order article via Infotrieve]
  30. Dennis, M. S., Henzel, W. J., Pitti, R. M., Lipari, M. T., Napier, M. A., Deisher, T. A., Bunting, S., and Lazarus, R. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2471-2475 [Abstract]
  31. Knudsen, K. A., Tuszynski, G. P., Huang, T.-F., and Niewiarowski, S. (1988) Exp. Cell Res. 179, 42-49 [Medline] [Order article via Infotrieve]
  32. Rucinski, B., Niewiarowski, S., Holt, J., Soszka, T., and Knudsen, K. A. (1990) Biochim. Biophys. Acta 1054, 257-262 [Medline] [Order article via Infotrieve]
  33. Staiano, N., Villani, G. R. D., Di Martino, E., Squillacioti, C., Vuotto, P., and Di Natale, P. (1995) Biochem. Mol. Biol. Int. 35, 11-19 [Medline] [Order article via Infotrieve]
  34. Mould, A. P., Komoriya, A., Yamada, K. M., and Humphries, M. J. (1991) J. Biol. Chem. 266, 3579-3585 [Abstract/Free Full Text]
  35. Adler, M., Lazarus, R. A., Dennis, M. S., and Wagner, G. (1991) Science 253, 445-448 [Medline] [Order article via Infotrieve]
  36. Green, L. J., Brierley, V. H., and Humphries, M. J. (1995) Biochem. Soc. Trans. 23, 505S [Medline] [Order article via Infotrieve]
  37. Akiyama, S. K., Yamada, S. S., Chen, W.-T., and Yamada, K. M. (1989) J. Cell Biol. 109, 863-875 [Abstract]
  38. Garcia-Pardo, A., Ferreira, O. C., Valinsky, J., and Bianco, C. (1989) Exp. Cell Res. 181, 420-431 [Medline] [Order article via Infotrieve]
  39. Makarem, R., Newham, P., Askari, J. A., Green, L. J., Clements, J., Edwards, M., Humphries, M. J., and Mould, A. P. (1994) J. Biol. Chem. 269, 4005-4011 [Abstract/Free Full Text]
  40. Mould, A. P., Akiyama, S. K., and Humphries, M. J. (1996) J. Biol. Chem. 271, 20365-20374 [Abstract/Free Full Text]
  41. Smith, D. B., and Johnson, K. S. (1988) Gene (Amst.) 67, 31-40 [CrossRef][Medline] [Order article via Infotrieve]
  42. Schagger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368-379 [Medline] [Order article via Infotrieve]
  43. Charo, I. F., Nannizzi, L., Smith, J. W., and Cheresh, D. A. (1990) J. Cell Biol. 111, 2795-2800 [Abstract]
  44. Kozlowski, J. M., Hart, I. R., Fidler, I. J., and Hanna, N. (1984) J. Natl. Cancer Inst. 72, 913-917 [Medline] [Order article via Infotrieve]
  45. Humphries, M. J., Akiyama, S. K., Komoriya, A., Olden, K., and Yamada, K. M. (1986) J. Cell Biol. 103, 2637-2647 [Abstract]
  46. Calvete, J. J., Schafer, W., Soszka, T., Lu, W., Cook, J. J., Jameson, B. A., and Niewiarowski, S. (1991) Biochemistry 30, 5225-5229 [Medline] [Order article via Infotrieve]
  47. Scarborough, R. M., Rose, J. W., Naughton, M. A., Phillips, D. R., Nannizzi, L., Arfsten, A., Campbell, A. M., and Charo, I. F. (1993) J. Biol. Chem. 268, 1058-1065 [Abstract/Free Full Text]
  48. Koivunen, E., Wang, B., and Ruoslahti, E. (1994) J. Cell Biol. 124, 373-380 [Abstract]
  49. Healy, J. M., Murayama, O., Maeda, T., Yoshino, K., Sekiguchi, K., and Kikuchi, M. (1995) Biochemistry 34, 3948-3955 [Medline] [Order article via Infotrieve]
  50. Dennis, M. S., Carter, P., and Lazarus, R A. (1993) Proteins Struct. Funct. Genet. 15, 312-321 [Medline] [Order article via Infotrieve]
  51. Lu, X., Williams, J. A., Deadman, J. J., Salmon, G. P., Kakkar, V. V., Wilkinson, J. M., Baruch, D., Authi, K. S., and Rahman, S. (1994) Biochem. J. 304, 929-936 [Medline] [Order article via Infotrieve]
  52. Rahman, S., Lu, X., Kakkar, V. V., and Authi, K. S. (1995) Biochem. J. 312, 223-232 [Medline] [Order article via Infotrieve]
  53. Lu, X., Rahman, S., Kakkar, V. V., and Authi, K. S. (1996) J. Biol. Chem. 271, 289-294 [Abstract/Free Full Text]
  54. Nowlin, D. M., Gorcsan, F., Moscinski, M., Chiang, S.-L., Lobl, T. J., and Cardarelli, P. M. (1993) J. Biol. Chem. 268, 20352-20359 [Abstract/Free Full Text]
  55. Cardarelli, P., Cobb, R. R., Nowlin, D. M., Scholz, W., Gorcsan, F., Moscinski, M., Yasuhara, M., Chiang, S.-L., and Lobl, T. J. (1994) J. Biol. Chem. 269, 18668-18673 [Abstract/Free Full Text]
  56. Lam, S. C.-T., Plow, E. F., Smith, M. A., Andrieux, A., Ryckwaert, J.-J., Marguerie, G., and Ginsberg, M. H. (1987) J. Biol. Chem. 262, 947-950 [Abstract/Free Full Text]
  57. Loftus, J. C., O'Toole, T. E., Plow, E. F., Glass, A., Frelinger, A. L., III, and Ginsberg, M. H. (1990) Science 249, 915-918 [Medline] [Order article via Infotrieve]
  58. Smith, J. W., and Cheresh, D. A. (1990) J. Biol. Chem. 265, 2168-2172 [Abstract/Free Full Text]
  59. Edwards, J. G., Hameed, H., and Campbell, G. (1988) J. Cell Sci. 89, 507-513 [Abstract]
  60. Humphries, M. J. (1990) J. Cell Sci. 97, 585-592 [Medline] [Order article via Infotrieve]
  61. Bjarnason, J. B., and Fox, J. W. (1995) Methods Enzymol. 248, 345-368 [Medline] [Order article via Infotrieve]
  62. Wolfsberg, T. G., Straight, P. D., Gerena, R. L., Huovila, A. J., Primakoff, P., Myles, D. G., and White, J. M. (1995) Dev. Biol. 169, 378-383 [CrossRef][Medline] [Order article via Infotrieve]
  63. Kratzschmar, J., Lum, L., and Blobel, C. P. (1996) J. Biol. Chem. 271, 4593-4596 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.